Australia's most trusted
source of pharma news
Monday, 06 May 2024
Posted 23 April 2024 AM
GSK is looking to shore up the position of its Shingles vaccine, Shingrix, with long-term efficacy data that up-and-coming rivals will need to wait to match.
Shingrix replaced MSD's live-attenuated vaccine Zostavax on Australia's National Immunisation Program in November last year after five years of being available in the country. However, Pfizer and BioNTech are collaborating on an mRNA Shingles vaccine, while Moderna is targeting the disease with its own mRNA vaccine.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.